Press

PharmaTher Provides Product Pipeline Updates and Anticipated Milestones for Q4-2021 and 2022

Sep 13 • 8 min read

Quick Take: For the rest of 2021, PharmaTher will focus on advancing three promising developments through FDA Phase 2 clinical studies PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, is pleased to provide a product pipeline update and anticipated milestones for Q4-2021 and 2022 including ongoing FDA Phase 2 clinical study programs, microneedle…

Hamilton Morris joins COMPASS Pathways to research new psychedelic compounds

Sep 10 • 3 min read

Quick Take: Hamilton Morris, creator of docu-series Hamilton’s Pharmacopeia, will engage with COMPASS as a full-time consultant, primarily working at their Discovery Center COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, has engaged Hamilton Morris, the research scientist and film-maker, as a…

Field Trip Health Ltd. to Pursue Treatment Resistant Depression and Postpartum Depression as Indications for FT-104

Sep 9 • 4 min read

Quick Take: FT-104, which acts similarly to psilocybin, will produce a shorter duration (2-3 hours) of psychoactivity than psilocybin. Field Trip Health Ltd. (NASDAQ: FTRP), a global leader in the development and delivery of psychedelic therapies, announced today the lead indications for FT-104, its novel psychedelic compound in development, will be Treatment Resistant Depression (TRD)…

Ketamine One Signs LOI for Two Ketamine Infusion Clinics in Texas

Sep 8 • 3 min read

Quick Take: The clinics will open in Austin and Bee Cave, Texas, and will be led by Illumma KetamineOne Capital Limited (NEO: MEDI) (OTC: KONEF), a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased to announce that it has recently entered into a non-binding letter of…

Journey Colab secures $12M Series A funding for Phase 1 trial of Mescaline HCl, JOUR-001, for treatment of Alcohol Use Disorder

Sep 8 • 3 min read

Quick Take: Journey Colab has raised $12M in equity to fund the development of synthetically-derived psychedelic products These products are aimed at treating alcohol addiction, among other mental health disorders. Journey Colab Corp., a privately-held psychedelic pharmaceutical startup initially funded by Sam Altman and Apollo Projects, has raised $12M in new equity funding to develop…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441